SYLVIA AND CHARLES VIERTEL CHARITABLE FOUNDATION MARKS 30 YEARS MILESTONE IN FUNDING RESEARCH New Fellowships to researchers in cancer metastasis, epigenomics and AI in early disease diagnosis & management
With
Associate Professor Paul Ekert, Co-Chair,
Medical Advisory Board, Sylvia and Charles Viertel Charitable Foundation
SEGMENT
Filmed in Sydney, Melbourne & Adelaide | December 2025
One of Australia’s largest charitable foundations, the Sylvia and Charles Viertel Charitable Foundation, is celebrating three decades of transforming Australian healthcare – with more than $90 million invested in medical research and a legacy of breakthroughs that are saving lives. Viertel Fellowships support some of Australia’s best and brightest researchers and clinicians, with 70 Fellowships awarded to date.
In late October 2025, the Sylvia and Charles Viertel Charitable Foundation, in association with Bellberry, announced the recipients of the 2025 Viertel Senior Medical Research Fellowships. Three Australian mid-career researchers who are advancing solutions for major illnesses including cancer, cardiovascular disease, and neurodegenerative diseases. The 2025 Viertel Senior Medical Research Fellows, who will each receive $1.375 million over five years to support their work, are:
- Dr Joanna Achinger-Kawecka, SAiGENCI for her work in advancing cancer therapy utilising innovative 3D chromatin structure mapping technology.
- Dr Dustin Flanagan, Monash Biomedicine Discovery Institute, Monash University, for addressing the impact of direct cell damage on gastric cancer initiation and progression.
- Associate Professor Zongyuan Ge, Monash AIM for Health Lab, Monash University for developing a personalised healthcare model integrating diverse patient information collected over time via AI. He is the recipient of a Bellberry-Viertel Senior Medical Research Fellowship.
The Viertel Foundation over 30 years has had significant impact in medical research, including
- Awarding 70 fellowships since 1995, each currently providing $1.375 million over five years to support Australia’s top mid-career researchers.
- 162 Clinical Investigator Awards providing $90,000 over one year have been granted, supporting early-career clinicians and stimulating clinical research across Australia.
- Research infrastructure grants totalling $2.45 million have been awarded, recognising the importance of establishing and maintaining the facilities required for world-class research environments.
- The combined total value of the Clinical Investigator Awards, the Fellowships, and infrastructure grants – including the most recent awards has reached $90,001,250. This substantial investment underscores the Foundation’s enduring commitment to advancing medical research and improving health outcomes for Australians.
- Funding has enabled breakthroughs in cancer, infectious diseases, respiratory illnesses, dementia, stem cell research, and more – directly impacting millions of Australians each year.
Source: Adapted from Equity Trustees media release
Photo Credit: Charles Viertel Photo, Queensland Eye Institute
Photo Credit: AAHMS Gala Dinner, Canberra November 2025, Australian Academy of Health and Medical Sciences
You Might also like
-
Report: Youth pathways to health services
The 2020 Youth Health Forum (YHF) was created to make young people’s ideas and experiences part of our national discussions about services for young Australians.
Healthcare professionals across Australia have long recognised the problem of young people falling through the gaps of a health system that wasn’t designed for them.
-
Care workforce challenges
In a wide ranging report looking at the carer needs across Australia, PwC Australia published Reimagine Care Workforce Solutions in October 2022.
Australian Health Journal spoke with Kerryn Dillon, Director Ageing and Reablement and Health Workforce at PwC Australia about the community care sectors of aged care, disability care and childcare the report covers.
-
Thyroid health into pregnancy
‘Without an adequate amount of thyroid hormone mothers can be exposed to hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia or eclampsia, which affect around 10% of pregnant women and are the leading causes of maternal and neonatal mortality worldwide. Mothers who suffer from hypertensive disorders during pregnancy are at increased risk of long-term cardiovascular consequences and hypertensive disorders in subsequent pregnancies. Evidence also indicates a risk of reduced cognitive ability to their offspring.
‘Knowing if you are genetically predisposed to Hashimoto’s or Graves’ Diseases, which are both thyroid autoimmune disorders is important to be aware of, to ensure all appropriate tests are ordered. Autoimmune disorders may predispose mothers to a thyroid problem during pregnancy’, says Professor Creswell Eastman, who also serves as the ATF’s Principal Medical Advisor.